<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542957858471">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">23.11.2018 07:24:18 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.17x219y6t5mzl</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>I&apos;m on holiday &lt;a href=&quot;http://sjofartsbygningen.no/endep-10mg-depression-7ef0.pdf&quot;&gt;endep 25 uses&lt;/a&gt;  The approval is primarily based on two Phase III studies which showed that Lemtrada (alemtuzumab) was significantly more effective than Merck KGaA&amp;rsquo;s Rebif (subcutaneous interferon beta-1a) at reducing relapse rates. Also, accumulation of disability was significantly slowed in patients taking the drug versus Rebif and Lemtrada-treated patients were significantly more likely to experience improvement in pre-existing disabilities.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
